safety and therapeutic value of ultrasound-guided percutaneous laser ablation for primary hyperparathyroidism (PHPT).
Methods:
Three patients with PHPT were treated with laser ablation. The multi-point ablation power was 3W
and the contrast-enhanced ultrasound was used to evaluate the ablation range immediately after surgery. The changes o
f intact parathyroid hormone (iPTH)
serum calcium
serum phosphorus
alkaline phosphatase (ALP) and parathyroid nodule volume were measured before and after operation for 12 months.
Results:
A total of 3 cases of PHPT nodules were completely ablated at one time
confirmed by contrast-enhanced ultrasound. 12 months after operation
iPTH decreased from (578.37 568.66) ng/L to (92.6219.83) ng/L
serum calcium decreased from (3.200.43) mmol/L to (2.350.03) mmol/L (
P
<0.05)
and ALP decreased from (303.53188.29) U/L to (99.707.86) U/L. Serum phosphorus rose from (0.8300.098) mmol/L to (0.9230.120) mmol/L. Postoperative iPTH decreased significantly. The blood calcium
blood phosphorus and ALP continued to be normal levels. The nodule volume reduction rate was >95.73%. One case of postoperative bone starvation syndrome was treated with oral calcium supplementation
and no serious complications such as recurrent laryngeal nerve injury occurred.
Conclusion:
Ultrasound-guided percutaneous laser ablation of PHPT is a minimally invasive
safe and effective method
which can significantly reduce iPTH
serum calcium measurements and significantly reduce the volume of parathyroid nodules. It can be a new method for the treatment of PHPT.